Testing lenvatinib plus TACE and immunotherapy before liver surgery
Part of Cancer clinical trials.
This study tests whether a combination of the drug lenvatinib, a liver treatment called TACE, and the immunotherapy drug camrelizumab can shrink advanced hepatocellular carcinoma enough to make surgery (or “conversion resection”) possible. It may help some people live longer by improving the chance that the cancer can be removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have liver cancer (HCC) confirmed by scan criteria, biopsy, or fluid tests.
- You have not had cancer medicines for HCC before (except you may have had two or fewer TACE procedures).
- Your overall health score (ECOG) is 0 or 1, meaning you can do most daily activities.
- Your liver function is in the Child-Pugh A to B range, and your heart function and blood counts meet study lab requirements.
- You will need HBV/HCV tests to be controlled (if you have hepatitis B) or negative (for hepatitis C), and you must not be planning a pregnancy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a focused radiation beam (SBRT) plus a pill that helps stop tumor blood vessel growth (lenvatinib) and a procedure that blocks blood flow to the tumor (TACE) for people with advanced liver cancer that has not yet spread outside the liver. The goal is to see if this triple therapy can improve outcomes without prior treatment.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This trial tests whether giving pembrolizumab (an immune therapy) and lenvatinib (a targeted pill) before planned liver surgery can improve outcomes for people with certain types of operable hepatocellular carcinoma (HCC). It’s meant for tumors that can be removed with curative intent, but still carry a risk of coming back.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
This study compares a stronger treatment plan (lenvatinib plus sintilimab plus TACE) against a standard plan (lenvatinib plus TACE) for advanced liver cancer. It aims to see which plan works better to control tumors and help patients live longer.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.